Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Other

Sigma-tau Healthscience S.p.a.

Avantgarde LLC

Sigma-tau

Spa Societa Prodotti Antibiotici S.p.a.

Advantgarde S.p.a.

Alfasigma S.p.a.

Claudio Cavazza

Maria Ornella Tinti

Paolo Cavazza

Domenico Misiti

Paolo De Witt

Menotti Calvani

Nazareno Scafetta

Claudio Pisano

Paolo Carminati

Aleardo Koverech

Loredana Vesci

Mose Santaniello

Emma Quaresima

Luigi Mosconi

Aldo Fassi

Maria T Ramacci

Nicola Fanto

Maria Giovanna Caccia

Giulio Taglialatela

Massimo Carloni

Stefania D'Iddio

Giovanni Valentini

It is described the use of L-carnitine and/or one or more alkanoyl L-carnitines, or mixture thereof, or one of their pharmaceutically acceptable salts, for the preparation of a medicament or a nutritional supplement useful for preventing or treating the Leber optic neuropathy.

Therapeutical method for the treatment of the Leber optic neuropathy

A combination is described comprising at least one omega-3 fatty acid, optionally esterified or salified, at least one statin, Coenzyme Q10, resveratrol, at least one policosanol, pantethine, selenium, and zinc. This combination is endowed with a synergistic effect and is useful in the treatment of disease forms due to insulin resistance and in cardiovascular diseases.

Composition containing statins and omega-3 fatty acids

The main object here is the use of omega-3 polyunsaturated fatty acids (as ethyl esters, hereinafter called 'n-3 PUFA') as a medicament, either alone or in combination with other therapeutic agents, for reducing mortality for a cardiovascular cause, in particular arrhythmia or for reducing hospitalization for any cause, in particular a cardiovascular cause and for the daily administration to patients with symptomatic heart failure (HF) for more than 3.5 years.

Long-term treatment of symptomatic heart failure

The present invention relates to the use of acetyl L-carnitine in combination with an anti hypertensive drug, and a statin, for the preparation of a medicament for the prevention or delay of onset of type 2 diabetes and its complications, in pre-diabetic patients with insulin resistance.

Method useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance

A composition is disclosed suitable for the prevention and/or treatment of disorders due to abnormal lipid metabolism, such as hypercholesterolaemia, atherosclerosis, hyperlipidaemia and obesity, and which can therefore take the form of a dietary supplement or of an actual medicine, comprising as characterizing active ingredients: (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof, and (b) chitosan or its derivatives and congeners.

Composition for the prevention and/or treatment of disorders due to abnormal lipid metabolism, comprising propionyl L-carnitine and chitosan

A composition is disclosed which is suitable for the prevention and/or treatment of cell and tissue abnormalities of exogenous, toxic or metabolic origin and suitable for reducing the toxic effects of cyclosporin-A and other immunosuppressive agents, which may take the form of a food supplement or of an actual medicine, containing as its active ingredients in combination or separately packaged: (a) propionyl L-carnitine or one of its pharmacologically acceptable salts, and (b) an amino acid selected from the group consisting of glycine, serine, alanine and arginine, or mixtures thereof.

Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents

A food selected from the group comprising milk and dairy products derived from milk, comprising a carnitine in an effective amount to stimulate, through the natural fatty acid metabolic processes that take place in a consumer of said food, the synthesis of polyunsaturated fatty acids from the saturated fatty acids originally contained in the food.

Food supplemented with a carnitine, suitable for stimulating the biosynthesis of polyunsaturated fatty acids from the saturated fatty acids contained in the food

A composition is disclosed which is suitable for the prevention and treatment of kidney dysfunctions and diseases and which can therefore take the form of a food supplement or of an actual medicinal drug comprising a combination of acetyl L-carnitine and propionyl L-carnitine or their pharmacologically acceptable salts.

Composition for the prevention and treatment of kidney dysfunctions and diseases

A food selected from the group comprising milk and dairy products derived from milk, comprising a carnitine in an effective amount to stimulate, through the natural fatty acid metabolic processes that take place in a consumer of said food, the synthesis of polyunsaturated fatty acids from the saturated fatty acids originally contained in the food, the synthesis of polyunsaturated fatty acid from the saturated fatty acids originally contained in the food.

The method for the treatment of chronic uremic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.

Treating chronic uremic patients undergoing periodical dialysis

A composition is disclosed which is suitable for the prevention and/or treatment of vasculopathic, cardiac, central and peripheral cerebral disturbances and for the prevention of learning disorders or disorders related to ageing, as well as for coping with increased energy requirements, and which may take the form of a dietary supplement or an actual medicine in its own right, containing the following as its characterising active ingredients: (a) propionyl L-carnitine or one of its pharmacologically acceptable salts; and (b) coenzyme Q .

Composition for prevention and/or treatment of vascular diseases, comprising propionyl L-carnitine and coenzyme Q10

A composition is disclosed suitable for the prevention and/or treatment of disorders due to abnormal lipid metabolism, such as hypercholesterolaemia, atherosclerosis, hyperlipidaemia and obesity, and which can therefore take the form of a dietary supplement or of an actual medicine, comprising as characterising active ingredients: (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof, and (b) chitosan or its derivatives and congeners.

Composition for the prevention and/or treatment of disorders due to abnormal lipid metabolism, comprising propionyl l-carnitine and chitosan

The present invention relates to a composition, which contains L-carnitine or alkanoyl-L-carnitine, and a glucosaminoglycan or a constituent thereof, suitable for the prevention of articular disorders and for the therapeutic treatment of articular diseases.

Combination composition in the form of nutritional supplement or pharmaceutical composition for the prevention and therapeutical treatment of degenerative or inflammatory articular disorders

Treating chronic uremic patients undergoing periodic dialysis

Patients suffering from diabetic and/or dysmetabolic nephropathy are treated with L-carnitine or its alkanoyl derivatives.

Use of L carnitine and its alkanoyl dervatives for the preparation of a medicament useful for the treatment of patients suffering from diabetic and/or dysmetabolic nephropathy

Growing community of inventors

Rome, Italy

Claudio Cavazza